Daniel Stauder
Stock Analyst at Citizens
(2.44)
# 2,484
Out of 5,238 analysts
25
Total ratings
45.83%
Success rate
4.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniel Stauder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AORT Artivion | Maintains: Market Outperform | $53 → $48 | $25.41 | +88.90% | 8 | May 8, 2026 | |
| LMAT LeMaitre Vascular | Maintains: Market Outperform | $118 → $127 | $107.94 | +17.66% | 6 | May 6, 2026 | |
| ATRC AtriCure | Maintains: Market Outperform | $60 → $52 | $26.28 | +97.87% | 7 | Feb 18, 2026 | |
| STXS Stereotaxis | Initiates: Market Outperform | $4 | $1.90 | +110.53% | 1 | Dec 16, 2025 | |
| STIM Neuronetics | Maintains: Market Outperform | $3 → $7 | $1.66 | +322.96% | 1 | Mar 5, 2025 | |
| AXON Axon Enterprise | Reiterates: Market Outperform | $725 | $403.54 | +79.66% | 1 | Feb 26, 2025 | |
| AVNS Avanos Medical | Reiterates: Market Perform | n/a | $24.80 | - | 1 | May 7, 2024 |
Artivion
May 8, 2026
Maintains: Market Outperform
Price Target: $53 → $48
Current: $25.41
Upside: +88.90%
LeMaitre Vascular
May 6, 2026
Maintains: Market Outperform
Price Target: $118 → $127
Current: $107.94
Upside: +17.66%
AtriCure
Feb 18, 2026
Maintains: Market Outperform
Price Target: $60 → $52
Current: $26.28
Upside: +97.87%
Stereotaxis
Dec 16, 2025
Initiates: Market Outperform
Price Target: $4
Current: $1.90
Upside: +110.53%
Neuronetics
Mar 5, 2025
Maintains: Market Outperform
Price Target: $3 → $7
Current: $1.66
Upside: +322.96%
Axon Enterprise
Feb 26, 2025
Reiterates: Market Outperform
Price Target: $725
Current: $403.54
Upside: +79.66%
Avanos Medical
May 7, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $24.80
Upside: -